On December 12, 2024, Pleno, a clinical and multi-omics diagnostics company that is revolutionizing biological target detection, announced that it has closed $25 million in Series B funding from major investors Deerfield Management, Foresite Capital, and Medical Excellence Capital, among others. Wilson Sonsini Goodrich & Rosati advised Pleno on IP diligence related to the transaction.

Based in San Diego, California, Pleno is an early-stage start-up company developing the RAPTOR™ multi-omic instrument platform to enable a broad array of life science applications. The company makes complex multi-omic known-target detection accessible and affordable to everyone through the innovative use of its Hypercoding™ technology, which simplifies the entire process and enables unprecedented improvements in performance, cost, and scale.

The Wilson Sonsini team advising Pleno on IP diligence related to the Series B included Bill Barrett, Sara Patak, and Matt Garnica.  

For more information, please see Pleno’s news release. Additional coverage is available in Fierce Biotech and the San Diego Business Journal.